resisttb
- Oct 12, 2022
- 1 min read

Drug-Resistant TB Trial Results Published in New England Journal of Medicine

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with reduced dosage and/or duration of the linezolid component of the regimen.1 Along with the maintenance of efficacy, there was a decrease in linezolid-associated side effects that accompanied the reduced dosage or duration of linezolid.1 The results from the trial, which was led by TB Alliance, a non-profit TB drug developer, were published today in the New England Journal of Medicine. Read more here.

Recent Posts

See All

endTB Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options

Clinical trial results presented for the first time at the Union World Conference on Lung Health revealed evidence to support the use of four new, improved regimens to treat multi-drug resistant tuber

New preventive treatment for children cuts the risk of drug-resistant tuberculosis by more than half

Clinical trial results presented in Paris at the Union World Conference on Lung Health showed that a once-daily dose of a widely available antibiotic over six months cut a child’s risk of developing m

Ending TB Is Within Reach — So Why Are Millions Still Dying?

Tuberculosis, which is preventable and curable, has reclaimed the title of the world’s leading infectious disease killer, after being supplanted from its long reign by Covid-19. But worldwide, 40 perc